Influence of mydriatics on choroidal thickness measurement using enhanced depth imaging-OCT

Min Kim, Hee Jung Kwon, Sungchul Lee

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

PURPOSE.: To evaluate the potential influence of mydriatics on choroidal thickness measurement using enhanced depth imaging optical coherence tomography (EDI-OCT). METHODS.: This was a randomized, double-blind, paired-eye study. Fifty-eight healthy eyes of 29 patients were included in this study, and one eye of each subject was designated randomly as experimental and the contralateral eye as control. A single drop of Mydrin-P (tropicamide and phenylephrine; Santen Pharmaceuticals, Japan) or a single drop of unpreserved saline was administered in the respective eyes of patients three times at 5-min intervals. Choroidal thickness (CT) was measured using EDI-OCT, and changes in CT before and after the administration of the eye drops were analyzed at the subfovea and at 0.5 mm intervals (to 3.0 mm) from the fovea at nasal, temporal, superior, and inferior locations. RESULTS.: Linear mixed-model analysis showed no significant changes in subfoveal CT after the administration of eye drops in either the mydriatics [from 313.00 ± 90.05 μm (before) to 316.34 ± 96.91 μm (after), p ≤ 0.500] or placebo group [from 311.07 ± 96.26 μm (before) to 313.14 ± 95.46 μm (after), p ≤ 0.248]. CT did not significantly differ within either group at other measured locations, as we moved further from the subfoveal starting point (all p > 0.05, linear mixed model). In evaluating a possible effect of mydriatics, we detected no significant difference in CT changes between the mydriatic test group and the saline placebo group at all intervals from the fovea (all p > 0.05, linear mixed model). CONCLUSIONS.: This study demonstrates that mydriatics (Mydrin-P) have no significant influence on clinical measurement of CT, as evaluated by EDI-OCT.

Original languageEnglish
Pages (from-to)1150-1155
Number of pages6
JournalOptometry and Vision Science
Volume89
Issue number8
DOIs
Publication statusPublished - 2012 Aug 1

Fingerprint

Mydriatics
Optical Coherence Tomography
Linear Models
Ophthalmic Solutions
Tropicamide
Placebos
Phenylephrine
Nose
Japan
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Optometry

Cite this

@article{7047939454b14764a5c8d61aefa7bdad,
title = "Influence of mydriatics on choroidal thickness measurement using enhanced depth imaging-OCT",
abstract = "PURPOSE.: To evaluate the potential influence of mydriatics on choroidal thickness measurement using enhanced depth imaging optical coherence tomography (EDI-OCT). METHODS.: This was a randomized, double-blind, paired-eye study. Fifty-eight healthy eyes of 29 patients were included in this study, and one eye of each subject was designated randomly as experimental and the contralateral eye as control. A single drop of Mydrin-P (tropicamide and phenylephrine; Santen Pharmaceuticals, Japan) or a single drop of unpreserved saline was administered in the respective eyes of patients three times at 5-min intervals. Choroidal thickness (CT) was measured using EDI-OCT, and changes in CT before and after the administration of the eye drops were analyzed at the subfovea and at 0.5 mm intervals (to 3.0 mm) from the fovea at nasal, temporal, superior, and inferior locations. RESULTS.: Linear mixed-model analysis showed no significant changes in subfoveal CT after the administration of eye drops in either the mydriatics [from 313.00 ± 90.05 μm (before) to 316.34 ± 96.91 μm (after), p ≤ 0.500] or placebo group [from 311.07 ± 96.26 μm (before) to 313.14 ± 95.46 μm (after), p ≤ 0.248]. CT did not significantly differ within either group at other measured locations, as we moved further from the subfoveal starting point (all p > 0.05, linear mixed model). In evaluating a possible effect of mydriatics, we detected no significant difference in CT changes between the mydriatic test group and the saline placebo group at all intervals from the fovea (all p > 0.05, linear mixed model). CONCLUSIONS.: This study demonstrates that mydriatics (Mydrin-P) have no significant influence on clinical measurement of CT, as evaluated by EDI-OCT.",
author = "Min Kim and Kwon, {Hee Jung} and Sungchul Lee",
year = "2012",
month = "8",
day = "1",
doi = "10.1097/OPX.0b013e318264f657",
language = "English",
volume = "89",
pages = "1150--1155",
journal = "Optometry and Vision Science",
issn = "1040-5488",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

Influence of mydriatics on choroidal thickness measurement using enhanced depth imaging-OCT. / Kim, Min; Kwon, Hee Jung; Lee, Sungchul.

In: Optometry and Vision Science, Vol. 89, No. 8, 01.08.2012, p. 1150-1155.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Influence of mydriatics on choroidal thickness measurement using enhanced depth imaging-OCT

AU - Kim, Min

AU - Kwon, Hee Jung

AU - Lee, Sungchul

PY - 2012/8/1

Y1 - 2012/8/1

N2 - PURPOSE.: To evaluate the potential influence of mydriatics on choroidal thickness measurement using enhanced depth imaging optical coherence tomography (EDI-OCT). METHODS.: This was a randomized, double-blind, paired-eye study. Fifty-eight healthy eyes of 29 patients were included in this study, and one eye of each subject was designated randomly as experimental and the contralateral eye as control. A single drop of Mydrin-P (tropicamide and phenylephrine; Santen Pharmaceuticals, Japan) or a single drop of unpreserved saline was administered in the respective eyes of patients three times at 5-min intervals. Choroidal thickness (CT) was measured using EDI-OCT, and changes in CT before and after the administration of the eye drops were analyzed at the subfovea and at 0.5 mm intervals (to 3.0 mm) from the fovea at nasal, temporal, superior, and inferior locations. RESULTS.: Linear mixed-model analysis showed no significant changes in subfoveal CT after the administration of eye drops in either the mydriatics [from 313.00 ± 90.05 μm (before) to 316.34 ± 96.91 μm (after), p ≤ 0.500] or placebo group [from 311.07 ± 96.26 μm (before) to 313.14 ± 95.46 μm (after), p ≤ 0.248]. CT did not significantly differ within either group at other measured locations, as we moved further from the subfoveal starting point (all p > 0.05, linear mixed model). In evaluating a possible effect of mydriatics, we detected no significant difference in CT changes between the mydriatic test group and the saline placebo group at all intervals from the fovea (all p > 0.05, linear mixed model). CONCLUSIONS.: This study demonstrates that mydriatics (Mydrin-P) have no significant influence on clinical measurement of CT, as evaluated by EDI-OCT.

AB - PURPOSE.: To evaluate the potential influence of mydriatics on choroidal thickness measurement using enhanced depth imaging optical coherence tomography (EDI-OCT). METHODS.: This was a randomized, double-blind, paired-eye study. Fifty-eight healthy eyes of 29 patients were included in this study, and one eye of each subject was designated randomly as experimental and the contralateral eye as control. A single drop of Mydrin-P (tropicamide and phenylephrine; Santen Pharmaceuticals, Japan) or a single drop of unpreserved saline was administered in the respective eyes of patients three times at 5-min intervals. Choroidal thickness (CT) was measured using EDI-OCT, and changes in CT before and after the administration of the eye drops were analyzed at the subfovea and at 0.5 mm intervals (to 3.0 mm) from the fovea at nasal, temporal, superior, and inferior locations. RESULTS.: Linear mixed-model analysis showed no significant changes in subfoveal CT after the administration of eye drops in either the mydriatics [from 313.00 ± 90.05 μm (before) to 316.34 ± 96.91 μm (after), p ≤ 0.500] or placebo group [from 311.07 ± 96.26 μm (before) to 313.14 ± 95.46 μm (after), p ≤ 0.248]. CT did not significantly differ within either group at other measured locations, as we moved further from the subfoveal starting point (all p > 0.05, linear mixed model). In evaluating a possible effect of mydriatics, we detected no significant difference in CT changes between the mydriatic test group and the saline placebo group at all intervals from the fovea (all p > 0.05, linear mixed model). CONCLUSIONS.: This study demonstrates that mydriatics (Mydrin-P) have no significant influence on clinical measurement of CT, as evaluated by EDI-OCT.

UR - http://www.scopus.com/inward/record.url?scp=84864680764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864680764&partnerID=8YFLogxK

U2 - 10.1097/OPX.0b013e318264f657

DO - 10.1097/OPX.0b013e318264f657

M3 - Article

C2 - 22797514

AN - SCOPUS:84864680764

VL - 89

SP - 1150

EP - 1155

JO - Optometry and Vision Science

JF - Optometry and Vision Science

SN - 1040-5488

IS - 8

ER -